News

Scheduled to enroll a minimum of 48 patients from Asia Pacific geographies, the multicenter, placebo-controlled, double-blind study will randomize the subjects into one active treatment arm or one

Leveraging an asset management approach, the new software improves cooperation and provides the automation of documents used throughout the drug product life cycle, from pre-clinical through product registration

The Supplemental New Drug Application (sNDA) of Mycamine is also indicated for patients with prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplants (HSCT). Astellas Pharma

Offered through the company’s existing wholesaler and pharmacy channels, the generic product that is indicated for erectile dysfunction in adult men had already been launched in Spain, Canada

Under the terms of the agreement, ADC Therapeutics has licensed a VivaMab antibody, VM101, produced using BioAtla’s Express Humanization, Comprehensive Positional Evolution, Combinatorial Protein Synthesis affinity and functional

The eClinical OS Marketplace enables customers to request and receive services directly and further allowing study sponsors and CROs to run studies more efficiently. Merge has joined hands

Albiglutide is an investigational glucagon-like peptide receptor agonist (GLP-1), which is an investigational once a week treatment for type 2 diabetes. Comprising eight individual studies (Harmony 1 to

The data from ORAL Start (A3921069), a 24-month Phase 3 randomized trail conducted in methotrexate (MTX)-naïve patients with moderately to severely active RA is included in the sNDA.

Vedolizumab is indicated for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC), the two most common types of inflammatory bowel